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L-3-n-butylphthalide (L-NBP) is a naturally occurring antioxidant, which can be used for the treatment 
of acute ischemic stroke and vascular dementia. This study evaluated the safety, tolerability and 
pharmacokinetics of L-NBP tablets in healthy Chinese volunteers. This was a single-center, randomized, 
double-blind, placebo-controlled, single- and multiple-dose study. Subjects were assigned to receive a 
single dose of L-NBP tablet at either 80, 160, 320, or 480 mg (n=40), or multiple doses of 160 mg twice 
daily for 7 days (n=12). Plasma samples were analyzed with LC-MS/MS. Pharmacokinetic parameters of 
L-NBP were calculated using non-compartmental analysis with WinNonlin software. Statistical analysis 
was performed using SPSS software. All adverse events (AEs) were mild and of limited duration; AEs 
in this study occurred less frequently and more mildly than AEs listed for the DL-NBP soft capsule. No 
serious adverse event (SAE), death or withdrawal from the study was observed. In the single-dose study, 
Cmax was reached at about 1 h, and the mean t1/2 was approximately 13.76 h. Area under curve (AUC) and 
Cmax increased with dose escalation, but dose proportionality was not observed over the range of 160 to 
480 mg. In the multiple-dose study, the steady-state was reached within 3 days with slight accumulation. 
In summary, the L-NBP tablet was well tolerated in healthy Chinese subjects. Slight accumulation 
appeared after repeated doses.
Uniterms: L-3-n-butylphthalide/tablets/safety. L-3-n-butylphthalide/tablets/tolerability. L-3-n-
butylphthalide/tablets/pharmacokinetics. Natural antioxidant.
L-3-n-butilftalida (L-NMP) é um antioxidante natural, que pode ser utilizado para o tratamento do acidente 
isquêmico agudo e demência vascular. Este estudo avaliou segurança, tolerância e farmacocinética de 
comprimidos de L-NBP em chineses voluntários sadios. Este foi um estudo monocêntrico, randomizado, 
duplo cego, com controle por placebo e doses única e múltipla. Os indivíduos receberam dose única de 
comprimido de L-NBP de 80, 160, 320 ou 480 mg (n=40) e doses múltiplas de 160 mg duas vezes ao dia, por 
sete dias (n=12). Amostras de plasma foram analisadas com LC-MS/MS. Os parâmetros farmacocinéticos 
do L-NBP foram calculados utilizando análise não compartimental, com o programa WinNonlin. A análise 
estatística foi realizada utilizando-se o programa SPSS. Todos os eventos adversos (EAs) foram moderados 
e de duração limitada. EAs nesse estudo ocorreram menos frequentemente e mais moderadamente do que 
os EAs relacionados para cápsulas moles de DL-NBP. Não se observaram eventos adversos graves (EAG), 
morte ou abandono do estudo. Com dose única, atingiu-se o Cmax em cerca de 1 hora e o t1/2 médio foi de, 
aproximadamente, 13,76 h. A área sob a curva (ASC) e o Cmax aumentaram com o aumento da dose, mas não 
se observou proporcionalidade na faixa acima de 160 a 480 mg. No estudo de dose múltipla, o equilíbrio 
foi alcançado em três dias, com pequeno acúmulo. Em resumo, o comprimido de L-NMP foi bem tolerado 
em indivíduos chineses saudáveis. O acúmulo pequeno apareceu após doses repetidas. 
Unitermos: L-3-n-butilftalida/comprimidos/segurança. L-3-n-butilftalida/comprimidos/tolerabilidade. 
L-3-n-butilftalida/comprimidos/farmacocinética. Antioxidante natural.
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INTRODUCTION
L-3-n-butylphthalide (L-NBP) can be extracted 
from the seeds of Chinese celery (Apiumgraveolens Linn.) 
(Chang, Wang, 2003). L-NBP has been shown to reduce 
β-amylase-induced neuronal apoptosis and to improve 
cognitive function in Alzheimer’s disease animal models 
(Peng et al., 2009; Peng et al., 2012; Peng et al., 2010; 
Peng et al., 2008; Xiang et al., 2014). Additionally, L-NBP 
has been demonstrated to ameliorate cognitive deficits 
and neuronal loss in the hippocampus of mice exposed to 
repetitive cerebral ischemia and reperfusion (Huai et al., 
2013). L-NBP might, therefore, be used for the treatment 
of acute ischemic stroke and vascular dementia.
3-n-butylphthalide (NBP) is a chiral molecule that 
has three different stereo isomers known as L-, DL-, 
and D-NBP. Preclinical studies have demonstrated that 
L-NBP induces the strongest biological response of the 
NBP isomers in the vast majority of evaluations; similarly, 
the toxicity of L-NBP is lower than other NBP isomers. 
A phase I study of L-NBP sodium chloride injection was 
carried out at the Second Affiliated Hospital of Soochow 
University in 2008. L-NBP was absorbed rapidly, with 
Cmax reached within 1 h; in this study, Cmax and AUC were 
shown to be dose-proportional over the 40-120 mg range. 
The steady-state conditions were achieved within 3 days 
after daily administration of 70 mg L-NBP sodium chloride 
injection (Wang et al., 2014). DL-NBP soft capsules were 
approved for production in China in 2005. A phase IV 
clinical study showed that DL-NBP soft capsules could 
improve neurological deficits and promote the recovery 
of neurological function in acute ischemic stroke patients.
The aim of this study was to evaluate the safety, 
tolerability and pharmacokinetics of L-NBP tablets after 
single- and multiple-doses in healthy Chinese volunteers.
MATERIAL AND METHODS
Drug and reagents
Four dosages (80 mg, 160 mg, 320 mg and 480 mg) 
of L-NBP tablets (Batch: 20080901, Specifications: 80 mg/
tablet) for single- and multiple-dose were made. L-NBP 
reference substance (Batch: 040708, purity: 99.7%) was 
obtained from the Zhongqi Pharmacy of CSPC Pharma, 
Shijiazhuang, China. Diazepam reference substance 
(internal standard, IS, Batch: 1230-9601, purity: 100.0%) 
was purchased from the National Narcotic Drug Laboratory, 
China. Methanol and formic acid (HPLC grade) were 
purchased from Tedia Company, Inc. (Fairfield, OH, USA). 
All other chemicals were of analytical grade.
Instruments
HPLC was performed using a 1200 Series device 
(Agilent Technologies, Palo Alto, CA, USA). Mass-
spectrometric detection was performed on an API 4000 
triple-quadrupole instrument (ABI-SCIEX, Ontario, 
Canada).
Subjects
Healthy Chinese volunteers, aged 19-45, with a body 
mass index (BMI) of 19-24 kg/m2,and a body weight of 
more than 50 kg were eligible for inclusion in the study. 
Subjects were ascertained to be healthy through medical 
interview, physical examination, vital signs, clinical 
laboratory tests (e.g. hematology, blood chemistry and 
urinalysis), 12-lead electrocardiogram (ECG) and chest 
X-ray within 2 weeks before the first dosing of the study 
medication. Female subjects had to be using double barrier 
contraception or surgically sterilized.
The study was performed in accordance with the 
principles of the Declaration of Helsinki and Good Clinical 
Practice (GCP) in China. The study protocol was reviewed 
and approved by the Independent Ethics Committee of 
the Second Affiliated Hospital of Soochow University 
(approval numbers: 200814 and 200904). All subjects 
provided written informed consent prior to entering the 
study.
Study design
This was a single-center, randomized, double-blind, 
placebo-controlled, single- and multiple-dose study. In 
the single-ascending-dose (SAD) study, subjects were 
assigned to receive a single oral administration of L-NBP 
tablet or placebo (80, 160, 320 or 480 mg). The study 
drug to placebo ratio was 3:1 in the 160, 320 and 480 mg 
groups. No placebo was used in group 80 mg group. In 
the multiple- dose (MD) study, after the single-dose phase, 
from day 1 to day 3, subjects were assigned to receive oral 
administration of 160 mg L-NBP tablet or placebo, twice 
daily from day 3 to day 9. The study drug to placebo ratio 
was 10:2 in this group.
Blood samples (4 mL at each time point) were taken 
for PK analysis in the 160, 320, and 480 mg dosage groups 
at 0 h (pre-dose) and at 20 min, 40 min, 1, 1.5, 2, 2.5, 3, 4, 
5, 8, 12, 24, 36 and 48 h after dosing in the SAD study. For 
the pharmacokinetic assessment in the MD study, blood 
samples were collected at the same time points as in the 
SAD study, up to 48 h after dosing on day 1 and day 9. 
Blood samples were also collected prior to dosing from 
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day 6 to day 8, to determine trough concentrations. Blood 
samples were collected into heparinized vacutainers and 
centrifuged at 3200×g at 4 °C for 10 min. All of the plasma 
samples were stored at -40 °C until analysis.
Strenuous physical activities, smoking and 
consumption of alcohol or caffeine-containing beverages 
were prohibited throughout the study.
Analytical methods
Plasma concentrations of L-NBP were determined 
using a validated liquid chromatography, coupled with 
tandem mass spectrometry (LC-MS/MS) method (Shi, 
Hua, Zhang, 2010). This consisted of the following 
steps: 200 μL of plasma, 50 μL of diazepam (IS) working 
solution, and 600 μL of precipitant (methanol) were mixed 
in a 1.5 mL polypropylene tube for 1 min and centrifuged 
at 23,755×g at 4 °C for 10 min. In total, 20 μL of the 
supernatant was injected into the LC-MS/MS (API 4000, 
Applied BiosystemSciex, Ontario, Canada). Each 0.1 
mL volume of urine was centrifuged at 23,755×g at 4°C 
for 10 min, and 20 μL of the supernatant was injected for 
analysis. The analyte was separated on an XTerra® RP18 
column (150 mm × 4.6 mm; id, 5 μm) (Waters, Ireland) 
with methanol-2.5 mmol/L ammonium acetate (0.1% 
formic acid included) (85:15, v/v) as the mobile phase, 
at a flow rate of 1 mL/min. The MS/MS was carried out 
in the positive ionization mode with L-NBP and IS being 
identified by multiple reactions monitoring (MRM) at 
m/z 191.1→145.1 and m/z 285.1→193.1, respectively. 
The analysis time for each run was about 3 min. This 
method was validated over the concentration range of 
1-2000 ng/mL for all analytes in this study. The lower 
limit of quantification (LLOQ) was 1 ng/mL. Inter- and 
intra-batch precision were less than 15% and the accuracy 
was within 85-115%. A matrix-effect test indicated that the 
determination was not affected by the matrix. In addition, 
L-NBP in plasma was demonstrated to be stable under 
various storage conditions (e.g. -40 °C for at least 49 days; 
room temperature for 6 h; 3 freeze–thaw cycles; automatic 
sampler for 6 h). Low-, medium-, and high-quality control 
samples (2, 12, 120, 1600 ng/mL) were analyzed with the 
study samples to ensure the quality of analysis.
Pharmacokinetic assessment and statistical 
analysis
Pharmacokinetic analysis was performed with 
WinNonlin software (Version 6.3, Pharsight Corporation, 
Mountain View, CA, USA), utilizing non-compartmental 
analysis. The maximum plasma concentration (Cmax) 
and time to Cmax (tmax) were directly obtained from the 
concentration-time curves. The terminal-phase elimination 
half-life (t1/2) was calculated as 0.693/λz, where λz 
was the slope of the apparent elimination phase of the 
natural logarithmic (ln) transformation of the plasma 
concentration-time curve, which was estimated using liner 
regression. The area under the plasma concentration-time 
curve from time zero to t (AUC0–t), in which t is the time 
of last measurable sample, was calculated according to 
the linear trapezoidal rule. The AUC from time zero to 
infinity (AUC0–∞) was estimated as AUC0–t+Ct/λz, in which 
Ct was the plasma concentration of the last measurable 
sample. Apparent total clearance (Cl/F) was calculated as 
Dose/AUC0–∞ or Dose/AUCss, and apparent total volume of 
distribution (Vz/F) was calculated as CL/λz. Attainment of 
steady state by day 9 was evaluated by regressing the natural 
logarithmic (ln) transformation of trough concentrations 
on days 6, 7, 8, and 9 over time. Steady-state was reached 
if the slope was not statistically different from zero. The 
steady-state AUCs (AUCss) over the dosing interval 
(τ=12 h) and Cavg (AUCss/τ) were calculated. The degree 
of fluctuation (DF) was calculated as (Cmax–Cmin)/Cavg. 
Accumulation ratios were defined as the steady-state 
AUC0–τ to the single-dose AUC0-τ ratio or the steady 
state Cmax to the single-dose Cmax ratio, namely, RAUC = 
AUC0–τ (steady state)/AUC0–τ (single-dose) (τ=12 h) and 
RCmax=Cmax(steady state)/Cmax (single-dose), respectively.
Statistical analysis was performed using SPSS 
software (version 17.0, SPSS, Inc, Chicago, IL, USA). 
Prior to the analysis, dose-dependent parameters (Cmax 
and AUC) were determined using natural logarithms 
of individual values. For the exploration of dose 
proportionality, the slope β and 90% confidence intervals 
(CIs) obtained from the power model as ln(AUC or 
Cmax) = α + β × ln (dose) were computed by covariance 
(ANCOVA). The regression coefficient was significant 
at level 0.1. The pre-defined criterion was set as (0.500, 
2.000) (Hummel et al., 2009), and the criterion interval 
resulted in the value of (0.3691, 1.631). The differences 
in pharmacokinetic parameters among dose groups were 
compared using the analysis of variance (ANOVA), except 
for tmax, for which the non-parametric test (NPT) was 
used. Statistical comparisons between pharmacokinetic 
parameters of single and multiple doses were performed by 
the paired t-test (PTT). The differences in Cmin on days 6, 7 
and 8 were compared using ANOVA to determine whether 
the steady state was reached in the multiple-dose study.
Safety and tolerability assessment
AEs, physical examinations, clinical laboratory 
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tests, 12-lead ECGs and vital signs were monitored for 
safety and tolerability assessment. The relationship of AEs 
to the study drugs were graded as not related, probably 
not related, possibly related, probably related or definitely 
related. All adverse events were coded using the Medical 
Dictionary for Regulatory Activities (MedDRA®).
RESULTS
Subjects
A total of 52 subjects were enrolled in this study 
(40 in the SAD study and 12 in the MD study). All 
subjects completed this study. Table Ι summarizes the 
demographics of subjects. In general, subjects in different 
treatment groups were comparable in age, weight, BMI 
and metabolic measurements.
Pharmacokinetic assessment
The mean plasma concentration-time profiles of 
L-NBP following single-dose administration are shown 
in Figure 1; the pharmacokinetic parameters are presented 
in Table II. The results indicate that L-NBP was absorbed 
rapidly, with a median tmax of 1 h, 1 h and 1.5 h across the 
study doses. The mean t1/2 of L-NBP was similar across all 
doses, ranging from 11.87 to 14.79 h. Over the dose range 
of 160 to 482 mg, the mean Cmax increased from 241 to 
1008 μg/L, AUC0-t increased from 569.5 to 2711.9 h·μg/L, 
and AUC0-∞ increased from 594.5 to 2827.4 h·μg/L. The 
predefined range for dose proportionality was (0.3691, 
1.631). However, the mean slopes (90% CIs) were 1.420 
(0.946, 1.894) for Cmax, 1.498 (1.053, 1.942) for AUC0-t, 
and 1.478 (1.042, 1.915) for AUC0-∞. The 90% CIs for the 
ratio of dose-normalized of Cmax and AUC indicated that 
there was no apparent dose-proportionality over the range 
of 160 to 480 mg. The values of tmax and t1/2 were dose-
independent (P>0.05).
The mean plasma concentration-time profiles of 
L-NBP after the first dose on day 1 and the last dose on 
day 9 are presented in Figure 2; the pharmacokinetic 
parameters from the non-compartmental analysis of 
measured plasma concentrations on day 1 and day 9 are 
presented in Table III. No significant difference in Cminss 
was found by ANOVA analysis, indicating that the steady 
state conditions were reached within 3 days after twice 
daily dosing. Under steady state conditions, L-NBP was 
rapidly absorbed with a median tmax of 1.50 h and a mean 
Cmax of 217 μg/L, which was identical to the single-dose 
parameters on day 1. The tmax showed no significant 
difference between the first and the last dose. The t1/2 
showed significant difference between the first and the 
TABLE I - Summary of demographic data
Characteristic 
Single ascending dose Multiple dose
L-NBP L-NBP
placebo
L-NBP
placebo
L-NBP
placebo
L-NBP
placebo
80 mg 160 mg 320 mg 480 mg
160 mg twice 
daily for 7 d
n 4 9 3 9 3 9 3 10 2
Gender
male 2 5 1 4 2 4 2 5 1
female 2 4 2 5 1 5 1 5 1
Age (y) 22 ± 1 23 ± 2 24 ± 2 23 ± 2 25 ± 3 23 ± 2 21 ± 1 23 ± 3 21 ± 0 
Bodyweight (kg) 61.4 ± 9.8 59.5 ± 9.2 59.7 ± 5.5 58.7 ± 7.1 63.7 ± 9.3 56.5 ± 5.0 58.5 ± 7.6 56.1 ± 6.4 52.3 ± 3.2
Height (cm) 167.5± 6.6 166.9 ± 11.2 165.3 ± 6.4 165.6 ± 7.9 170.0 ± 14.0 164.5 ± 7.2 168.3 ± 13.5 165.1 ± 7.7 161.0 ± 11.3
BMI (kg/m2) 21.8 ± 2.0 21.2 ± 1.2 21.8 ± 0.7 21.4 ± 1.3 22.2 ± 1.0 20.9 ± 1.5 20.6 ± 1.1 20.6 ± 1.2 20.3 ± 1.6
Data are mean ± SD unless stated otherwise. BMI=body mass index; SD=standard deviation.
FIGURE 1 - Mean plasma concentration-time curves following 
administration of a single oral dose of L-NBP tablet at 160, 320, 
or 480 mg in healthy Chinese subjects. Data are represented as 
mean ± standard error of the mean.
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last dose. The mean AUC values were slightly higher in 
multiple-dosing regimen than the corresponding values 
obtained after single-dose administration on day 1, and 
slight accumulation was found following multiple dosing 
of L-NBP tablets.
Safety and tolerability assessment
A total of 23 subjects (14 in the SAD study and 9 
in the MD study) among the 52 volunteers who received 
the drug investigational product (study drug or placebo) 
experienced AEs. In the SAD study, there were 25 AEs; 
23 in the study drug group and 2 in the placebo group, 
respectively. Among them, somnolence (n=2, 480 mg) 
occurred in the study drug group and was assessed to 
be possibly related to the study drug. In the MD study, 
there were 25AEs; 19 in the study drug group and 6 in the 
placebo group, respectively. Among them, somnolence 
(n=2), headache (n=1), slowness to respond (n=1), and 
nausea (n=1) occurred in the study drug group and were 
assessed to be possibly related to the study drug. All 
reported AEs were mild or moderate in intensity and there 
were no SAEs, deaths or withdrawals.
There were no significant clinical findings in the 
hematology tests, blood chemistry examinations, urine 
tests or ECGs in the safety assessment of the study 
subjects during the study periods, and all results were 
within normal ranges. Vital signs, including the blood 
pressure, pulse rate and body temperature, and the physical 
examination results of the SAD and MD study participants 
showed no clinically significant changes.
L-NBP tablet was safe and well tolerated when 
administered as single-dose at up to 480mg and multiple-
dose at 160 mg, twice daily for 7 days. All subjects were 
in good compliance.
TABLE II - Main pharmacokinetic parameters of L-NBP after single oral dose
Parameter 160 mg (n=9) 320 mg (n=9) 480 mg (n=9)
Cmax (μg/L) 241 ± 154 557 ± 354 1008 ± 265
tmax (h) 1.00 (0.67-3.00) 1.00 (0.67-3.00) 1.50 (1.00-2.50)
AUC0-t (h·μg/L) 569.5 ± 364.9 1392.5 ± 574.4 2711.9 ± 997.0
AUC0-∞ (h·μg/L) 594.5 ± 365.9 1452.0 ± 597.9 2827.4 ±1062.6
t1/2 (h) 11.87 ± 3.28 14.79 ± 2.93 14.61 ± 3.24
Cl/F (L/h) 364.2 ±181.6 259.2 ±112.2 209.3 ±125.0
Vz/F (L) 6421.6 ± 3826.2 5680.5 ± 3302.3 4547.9 ±3671.6
Pharmacokinetic data are presented as mean ± SD, except for tmax, which is shown as median (range).
TABLE III - Main pharmacokinetic parameters of L-NBP after 
multiple oral doses of 160 mg, with single dose on d 1, no 
treatment on d 2 and successive dosing twice daily from d 3 
to d 9
Parameter single dose 
(d 1)
multiple dose 
(d 9)
Cmax (μg/L) 266 ± 233 217 ±165
tmax (h) 1.25 (1.00 – 4.00) 1.50 (1.00 – 4.00)
AUC0-t (h·μg/L) 563.4 ± 320.1 1022.4 ±337.7
AUC0-∞ (h·μg/L) 585.7 ± 320.0 1245.2 ± 382.3
t1/2 (h) 12.35 ± 5.91 22.73 ± 8.61
Vz/F (L) 5601.3 ± 3161.3 10011.03 ± 5793.07
Cl/F (L/h) 330.1 ± 129.7 290.7± 105.0
Cavg (μg/L) 51.5 ± 18.3
AUCSS (h·μg/L) 617.4± 220.2
DF 3.70
Rcmax 0.82
RAUC 1.45
Pharmacokinetic data are presented as mean ± SD, except for 
tmax, which is shown as median (range).
FIGURE 2 - Plasma concentration-time curves following a single 
dose or multiple doses (steady state) of L-NBP tablet 160 mg 
twice daily for 7 days. Data are presented as mean ± standard 
error of the mean.
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DISCUSSION
The current study characterizes the pharmacokinetic, 
safety and tolerability profiles of L-NBP tablets in healthy 
Chinese volunteers undergoing either single or twice-
daily dosing regimens. The doses selected were based on 
findings from the preclinical studies and the phase I study 
of the DL-NBP soft capsule, carried out at the Peking 
Union Medical College Hospital in 2004. L-NBP was 
absorbed rapidly after administration of a single-dose, with 
Cmax reached within approximately 1 h. The steady-state 
conditions were achieved within 3 days after twice daily 
dosing of the 160 mg L-NBP tablet.
The main AEs of the listed DL-NBP soft capsule are 
moderately elevated aminotransferase, nausea, abdominal 
discomfort, skin rashes and mental symptoms. In the 
current study, the AEs of the L-NBP tablet occurred less 
frequently and were and milder than those listed for the 
DL-NBP soft capsule. Somnolence, headache, slowness to 
respond, and nausea were assessed to be possibly related 
to the study drug. Among them, somnolence occurred in 
the high single-dose group (480 mg), and the other AEs 
occurred after multiple dosing.
In the SAD study, both Cmax and AUC increased with 
dose escalation, but dose proportionality was not observed 
over the range of 160 to 480 mg. The values of tmax and 
t1/2 were dose-independent. The mean t1/2 of L-NBP was 
similar across all doses. The tmax of the L-NBP tablet was 
similar, but the t1/2 of the L-NBP tablet was longer, when 
compared to the listed DL-NBP soft capsule.
In the MD study, there was no difference in Cmin-ss, 
as detected by ANOVA analysis. The tmax showed no 
significant difference between the first and the last 
dose. The steady-state was reached within 3 days after 
twice daily dosing with the160 mg L-NBP tablet. The 
mean AUC0-t was slightly higher after multiple-dose 
administration (1022.4 ± 337.7 h·μg/L) than that obtained 
after single-dose administration (563.4 ± 320.1 h·μg/L), 
and the RAUC of 1.45 was for AUC0-τ (τ = 12 h). The t1/2 was 
longer after multiple-dose administration (22.73 ± 8.61 h) 
than that obtained after single-dose administration (12.35 
± 5.91 h), and showed significant differences. Therefore, 
slight accumulation was found after multiple doses. The 
pharmacokinetic behavior of the 160 mg L-NBP tablet 
administered twice daily for 7 days was similar to that 
of the 200 mg DL-NBP soft capsule administered every 
6 hours for 7 days. The pharmacokinetic parameters for 
the DL- NBP soft capsule were provided by the Zhongqi 
Pharmacy of CSPC Pharma. (Shijiazhuang, China).
All AEs were mild, of limited duration. There were 
no SAEs, death or withdrawal. However, it is necessary to 
evaluate the effect of long-term doses of the L-NBP tablet 
on the nervous system, cardiovascular system, ECG and 
vision in the future studies.
CONCLUSIONS
The present study demonstrated the safety, 
tolerability and pharmacokinetics of the L-NBP tablet 
after single or multiple doses in healthy Chinese subjects. 
L-NBP was absorbed rapidly, and both the Cmax and the 
AUC increased with dose escalation; dose proportionality 
was not observed over the range of 160 mg to 480 mg. The 
steady state was achieved within 3 days after twice daily 
dosing with the160 mg L-NBP tablet. Slight accumulation 
was found after multiple doses. The L-NBP tablet was well 
tolerated in healthy Chinese volunteers over the studied 
dose range.
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